文献速递肿瘤 PET/CT核素与放射性配体治疗

PSMA阳性寡转移灶定位对转移灶定向外照射放疗疗效的影响:一项多中心回顾性研究

Influence of localization of PSMA-positive oligo-metastases on efficacy of metastasis-directed external-beam radiotherapy-a multicenter retrospective study.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2020-01-30

该多中心回顾性研究分析359例根治性前列腺切除术后68Ga-PSMA PET阳性复发前列腺癌患者,评估寡转移灶部位对转移灶定向放疗(MDR)后生化无复发生存(BRFS)的影响。中位随访16个月,239/351(68%)无生化复发;寡转移灶位于盆腔外(寡全身组)者相比寡盆腔组BRFS显著更低,总体BRFS取决于转移模式。

要点

  • 359例RPE后PSMA PET阳性复发患者接受MDR,中位随访16个月时68%(239/351)无生化复发。
  • 寡全身组野内控制90/98(91%),野外汇进展44/96(46%);寡盆腔组野外汇进展28/154(18%)。

核心结论

  • 总体BRFS取决于转移性疾病模式。
  • PSMA PET阳性寡转移灶可考虑行MDR,但需考虑约三分之一患者在中位16个月随访内出现进展。

研究设计与样本

  • 多中心回顾性研究,纳入359例根治性前列腺切除术后68Ga-PSMA PET阳性复发的前列腺癌患者。
  • 采用Kaplan-Meier生存分析和Cox回归分析评估生化无复发生存(BRFS,定义PSA < 放疗后最低值+0.2 ng/mL)。
  • 所有患者初始临床无远处转移(cM0);MDR前中位PSA 1.2 ng/mL(范围0.04-47.5),35%(125/359)接受联合雄激素剥夺治疗(ADT)。

主要发现

  • 75例为前列腺窝局部复发,32例为盆腔淋巴结加局部复发,117例为盆腔淋巴结复发,51例为腹主动脉旁淋巴结转移伴或不伴局部区域复发,84例为骨或内脏转移伴或不伴局部区域复发。
  • MDR后中位PSA最低值0.23 ng/mL(范围<0.03-18.30);中位随访16个月(1-57),239/351(68%)无生化复发。
  • 寡全身组(远处淋巴结和/或远处转移)野内控制90/98(91%),野外汇进展44/96(46%);寡盆腔组(局部和/或盆腔淋巴结复发)野外汇进展28/154(18%)。

关键数值与推荐

  • BRFS定义:PSA < 放疗后最低值+0.2 ng/mL。
  • 寡全身组野内控制90/98(91%),野外汇进展44/96(46%)。
  • 寡盆腔组野外汇进展28/154(18%)。

临床怎么用

  • 作者认为,PSMA PET阳性寡转移灶可考虑行MDR,但需考虑约三分之一患者在中位16个月随访内出现进展。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Approximately 40-70% of biochemically persistent or recurrent prostate cancer (PCa) patients after radical prostatectomy (RPE) are oligo-metastatic in 68gallium-prostate-specific membrane antigen positron emission tomography (68Ga-PSMA PET). Those lesions are frequently located outside the prostate bed, and therefore not cured by the current standards of care like external-beam radiotherapy (EBRT) of the prostatic fossa. This retrospective study analyzes the influence of oligo-metastases' site on outcome after metastasis-directed radiotherapy (MDR). METHODS: Retrospectively, 359 patients with PET-positive PCa recurrences after RPE were analyzed. Biochemical recurrence-free survival (BRFS) (prostate-specific antigen (PSA) < post-radiotherapy nadir + 0.2 ng/mL) was assessed using Kaplan-Meier survival and Cox regression analysis. RESULTS: All patients were initially clinically without distant metastases (cM0). Seventy-five patients had local recurrence within the prostatic fossa, 32 patients had pelvic nodal plus local recurrence, 117 patients had pelvic nodal recurrence, 51 patients had paraaortic lymph node metastases with/without locoregional recurrence, and 84 patients had bone or visceral metastases with/without locoregional recurrence. Median PSA before MDR was 1.2 ng/mL (range, 0.04-47.5). Additive androgen deprivation therapy (ADT) was given in 35% (125/359) of patients. Median PSA nadir after MDR was 0.23 ng/mL (range, < 0.03-18.30). After a median follow-up of 16 months (1-57), 239/351 (68%) patients had no biochemical recurrence. Patients with distant lymph node and/or distant metastases, the so-called oligo-body cohort, had an overall in-field control of 90/98 (91%) but at the same time, an ex-field progress of 44/96 (46%). In comparison, an ex-field progress was detected in 28/154 (18%) patients with local and/or pelvic nodal recurrence (oligo-pelvis group). Compared with the oligo-pelvis group, there was a significantly lower BRFS in oligo-body patients at the last follow-up. CONCLUSION: Overall, BRFS was dependent on patterns of metastatic disease. Thus, MDR of PSMA PET-positive oligo-metastases can be offered considering that about one-third of the patients progressed within a median follow-up of 16 months.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Schmidt-Hegemann NS, Kroeze SGC, Henkenberens C, et al. Influence of localization of PSMA-positive oligo-metastases on efficacy of metastasis-directed external-beam radiotherapy-a multicenter retrospective study. Eur J Nucl Med Mol Imaging. 2020. PMID: 32002591. doi:10.1007/s00259-020-04708-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。